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Molecular Markers of Early-Stage Mycosis Fungoides
Yaohua Zhang1,2,7, Yang Wang1,3,7, Richard Yu1,7, Yuanshen Huang1, Mingwan Su1, Cheng Xiao1,
Magdalena Martinka4, Jan P. Dutz5, Xuejun Zhang6, Zhizhong Zheng2 and Youwen Zhou1,5,6
The lack of a specific marker differentiating early mycosis fungoides (eMF) from benign inflammatory dermatitis
presents significant difficulties in the assessment and management of suspected MF patients, which often leads
to delayed diagnosis and improper medical approaches. To address this, an investigation was carried out to
characterize positive identification markers for eMF by comparing eMF lesions with healthy skin and benign
inflammatory dermatitis, using high-throughput genomic transcription profiling. A total of 349 genes were
differentially expressed in eMF lesions compared with normal skin. These genes belong to pathways associated
with inflammation, immune activation, and apoptosis regulation. Most of them (N¼ 330) also demonstrated
significant upregulation in chronic dermatitis, making them nonideal markers for eMF. Among them, 19 genes
with specific enrichment in eMF lesions were identified that showed no significant upregulation in chronic
dermatitis. Two of them, TOX and PDCD1, showed high discrimination power between eMF lesions and
biopsies from benign dermatitis by RNA expression. Furthermore, TOX demonstrated highly specific staining of
MF cells in eMF skin biopsies in immunohistochemistry and immunofluorescence, including the early
epidermotropic cells in Pautrier’s microabscesses. This study demonstrates the potential of eMF-enriched
genes, especially TOX, as molecular markers for histological diagnosis of eMF, which currently is a major
diagnostic challenge.
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INTRODUCTION
The diagnosis of eMF (patch and early plaque mycosis
fungoides; Pimpinelli et al., 2005) has been a major
diagnostic challenge in dermatology. The difficulty arises
because of the lack of specific cellular or molecular markers
that can reliably differentiate the malignant T cells from the
abundant reactive T cells that are present not only in benign
inflammatory mimickers of eMF, but also in the eMF lesions
themselves. Because of the lack of sensitive and specific
histological markers, it takes months to even decades before a
conclusive diagnosis of MF can be made in many clinical
cases (Arai et al., 1991). The lack of a standardized and
reliable method for diagnosing MF presents significant
difficulties in the assessment and management of patients
suspected to have MF, in the development and evaluation of
therapies, and in establishing a long-term prognosis for
patients. Recognizing this difficulty, and in an attempt to
establish a standardized algorithm for making the diagnosis
of eMF, the International Society of Cutaneous Lymphomas
(ISCL) proposed an integrated clinical pathological algorithm
for diagnosing eMF (Olsen et al., 2007). Although this has
been accepted by many as a useful diagnostic system, clinical
experience with this system will be needed over a long period
of time to fully evaluate its clinical utility. In addition, further
modifications of this system have been proposed by Ferrara
et al. (2008). It is noteworthy that the molecular markers and
immunohistochemistry (IHC) markers considered as ancillary
diagnostic criteria by the ISCL are all negative markers: MF
skin biopsies are characterized by the loss of expression of
cellular and molecular markers such as CD7, CD2, CD3, and
CD26. Positive molecular markers for defining MF in general,
and eMF in particular, are lacking.
Therefore, we conducted an investigation to characterize
positive identification markers for MF by comparing eMF
lesions with healthy skin and skin affected by benign
inflammatory dermatoses (BID), such as chronic dermatitis
(CD), using high-throughput genomic screening tools
(complementary DNA microarrays). Although most of the
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preferentially expressed genes in eMF skin biopsies are also
present in benign inflammatory dermatitis, a set of 19 genes
were found to be significantly upregulated in eMF without
significant change in benign inflammatory dermatitis skin.
Two genes, TOX and PDCD1, showed significant upregulation
in confirmatory reverse transcription–coupled PCR, whereas
TOX further demonstrated strong and specific ability to label MF
cells in eMF skin biopsies by immunofluorescence (IF) and IHC.
These markers, especially TOX, may prove useful for the
diagnosis and management of MF patients in the near future.
RESULTS
Gene expression profiles of early-stage MF
To determine the gene expression characteristics of eMF,
two-colored comparative transcriptome analysis was per-
formed on 5 eMF samples (Table 1), 5 CD samples, and 15
normal skin (NS) samples, using a common internal control
that was prepared by mixing equal proportions of the 15 NS
messenger RNA samples. After verifying that the qualities of
the 25 microarrays were adequate (Supplementary Figure S1
online), a two-stepped data-mining approach was employed
using the GeneSpring bioinformatic software (version 7.3).
First, a volcano plot was devised to select the transcripts that
show significant differential expression in eMF compared
with NS (42-fold, Po0.05 after Bonferroni correction for
multi-testing, Figure 1a), which yielded 439 transcripts
(representing 349 unique genes, Supplementary Table S1
online). Almost all of the differentially expressed genes in MF
skin biopsies previously reported by others (Shin et al., 2007;
Litvinov et al., 2010) are confirmed in this list. The highest
expressed genes, such as CXCL10, CXCL9, GZMB, KIR2DS2,
and IFNG, are involved in chronic inflammation and immune
activation, suggesting the presence of broad-spectrum im-
mune activation in the eMF lesions. This was supported by
examining the pathways enriched in eMF (Supplementary
Table S2 online), using Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) Bioinformatics
Resources 6.7 (Huang da et al., 2009a, b). The eMF-
overexpressed genes point to significantly enriched pathways
of immune response against target cells, Lck and Fyn tyrosine
Table 1. Characteristics of subjects with early mycosis fungoides (N=21)
RT–PCR1
Pt no. Sex/age Ethnicity Disease duration MF lesion type Biopsy site Clonal TCR TOX PDCD1
12 M/56 Chinese 3 Y Patch Abdomen + + 
22 M/62 Chinese 2 Y Patch Flank + + +
3 F/62 Caucasian 6 Mo Patch Abdomen  + +
4 F/42 Caucasian 9 Y Patch R arm NA  
5 M/30 South Asian 7 Y Patch Back  + 
6 F/65 Caucasian 1 Mo Thin plaque L thigh +  
72 M/32 Caucasian 1 Y Patch L thigh  + +
8 M/59 East-Indian 8 Y Patch L scapula NA + +
92 M/46 East-Indian 10 Y Patch Back + + +
10 F/47 Chinese 10 Y Thin plaque L shin + + 
112 M/43 East-Indian 1 Mo Thin plaque L thigh + + +
12 M/65 Caucasian 30 Y Patch L buttock  + +
13 M/30 Chinese 6 Y Patch R buttock  + NA
14 M/28 Chinese 13 Y Patch Back   NA
15 M/52 Chinese 7 Y Thin plaque Back NA + NA
16 F/64 Chinese 2 Y Patch Buttock + + NA
17 F/47 Chinese 11 Y Thin plaque Arm NA + NA
18 F/48 Chinese 5 Y Patch Abdomen   NA
19 F/37 Chinese 10 Y Patch Buttock NA  NA
20 M/82 Chinese 2 Y Patch Back NA + NA
21 M/42 Chinese 5 Y Patch Abdomen +  NA
Abbreviations: F, female; L, left; M, male; Mo, months; MF, mycosis fungoides; NA, not available; Pt no., patient number; R, right; RT–PCR, reverse
transcription–coupled PCR; Y, years.
1Gene transcript abundance higher (+) or lower () than the highest of the 15 benign inflammatory dermatosis (BID) samples and 21 normal skin (NS)
samples.
2Samples used for complementary DNA (cDNA) microarray analyses.
‘‘+’’ Indicates present and ‘‘’’ indicates absent.
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kinase pathway, antigen processing and presentation, cas-
pase cascade in apoptosis, as well as T helper type 1/T helper
type 2 differentiation.
Differentially upregulated genes in eMF compared with CD
Further examination of the eMF-enriched genes showed that
the vast majority of them (N¼330) were not specific for eMF,
as they also showed significant (although at different degrees)
upregulation in CD (Figure 1b and Supplementary Table S1
online). To select the more likely candidates of eMF-selective
genes, a second step of filtering was performed by filtering
out these genes, leaving 19 genes with42-fold upregulation
(Po0.05 t-test after Bonferroni correction for multiple testing)
in eMF but with no significant upregulation in CD when
compared with NS (Table 2 and Figure 1c).
One of these genes, TOX, is a critical regulator of early
T-cell development, specifically during the transition from
CD4þCD8þ precursors to CD4þ T cells. However, upon
completion of this process, it is tightly suppressed, so that
normal mature CD4þ cells do not have significant expres-
sion of this protein (Wilkinson et al., 2002). Of the remaining
genes, nine genes (IL23R, TAGAO, HLADPB2, LY9, IL18BP,
TNFSF13B, IFITM1, TNFSF10, and LAT) are involved in
immune regulation, whereas seven genes are involved in cell
signal transduction (PYHIN1, SKAP1, GBP2, ETS1, AGAP2,
GNGT2, and PSME2). One gene, MGAT4A, regulates cell
adhesion. One gene, PDCD1, is a pro-apoptosis regulator.
To verify the findings, the two most significantly upregu-
lated eMF gene markers, TOX and PDCD1, were analyzed by
reverse transcription–coupled PCR using an expanded sample
set that included 21 eMF samples (Table 1), 15 BID (including
6 CD, 6 psoriasis, and 3 pityriasis rubra pilaris), and 21 NS
samples. As shown in Figure 1d and e, both genes, especially
TOX, demonstrated highly significant upregulation compared
with both BID and NS. Furthermore, receiver operating
characteristic curves were used to estimate the specificity and
sensitivity of these gene transcripts to distinguish eMF from
their benign mimickers. When the specificity was set at 100%,
the sensitivity was 71.3% for TOX and 60% for PDCD1. In
general, TOX and PDCD1 showed positive correlation with
each other, although two samples showed increased TOX
expression but not PDCD1 expression (Table 1).
10
a
c d
e
b
eMF BID
eMF BID
I b
I a
8
6
4
2
–8 –6 –4 –2 0
Expression ratio
TOX
PDCD1
50
40
**P < 0.0001
*P < 0.01
30
20
Co
pi
es
/1
0^
3 
G
AP
DH
Co
pi
es
/1
0^
3 
G
AP
DH
10
0
5
4
3
2
1
0
eMF (N=21) BID (N=15)
Groups
NS (N=21)
eMF (N=21) BID (N=15)
Groups
NS (N=21)
**
*
*
**
2 4 6 8
AGAP2
TNFSF10
GNGT2
ETS1
SKAP1
LY9
LAT
PYHIN1
TAGAP
TOX
MGAT4A
GBP2
PSME2
IFITM1
TNFSF138
IL18BP
PDCD1
IL23R
HLA-DPB2
Normal skin
Normal skin
–
 
Lo
g 
10
 (P
-
va
lu
e)
Figure 1. Identification of early mycosis fungoides (eMF)-specific genes. (a) Comparative transcriptome analyses of eMF were performed using the Agilent
G4112F whole human genome arrays as described in the text. The transcripts with 42-fold differential expression between eMF and normal skin (NS)
are depicted as red dots in the volcano plot using the GeneSpring software (version 7.3). (Line a) The threshold of P-values o0.05 without correction.
(Line b) The threshold of Po0.05, after Bonferroni correction for multiple testing. (b) The 439 transcripts differentially expressed in eMF relative to NS are plotted
as a heat map in a data set consisting of 25 transcriptomes analyzed, including 5 eMF, 5 benign inflammatory dermatoses (BID; all five were chronic dermatitis
(CD)), and 15 NS. (c) A heat map showing the 19 genes with significant upregulation in eMF (42-fold) but not in BID (o2-fold) when compared with NS.
(d, e) Quantification of TOX and PDCD1 transcripts (respectively) in eMF (N¼ 21), BID (N¼ 15, including 6 CD, 6 psoriasis, and 3 pityriasis rubra pilaris),
and NS (N¼ 21) using reverse transcription–coupled PCR (RT-PCR). The relative transcript levels are expressed as copies of TOX or PDCD1 per 1,000 copies
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts.
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The TOX antibody specifically labels CD4þ T cells in eMF but
not in CD or NS
TOX and PDCD1 were further evaluated for their ability to
identify CD4þ T cells in eMF biopsies with chronic
dermatoses as the controls, using IF and IHC. NS contained
few CD4þ T cells (data not shown). CD biopsies contained
variable numbers of CD4þ T cells. The vast majority did not
show any detectable staining of TOX by IF or IHC, although
some (o5%) showed dim and focal nuclear staining (Figure 2
and Table 3). In contrast, there was a marked increase of cells
with TOX staining in eMF samples. Not only did all eight eMF
samples contain much higher cell numbers with dim focal
nuclear TOX staining, but they also contained 11–69%
CD4þ T cells demonstrating bright diffused nuclear TOX
staining, whereas this pattern of staining was not observed in
any of the four CD samples (Figure 2 and Table 3). PDCD1
showed a membrane staining of CD4þ T cells in eMF
(Table 3 and Figure 3c), although this was not specific to eMF
as one of the four CD samples showed strong PDCD1
membrane staining.
TOX antibody was further evaluated by IHC, a technique
available in routine pathology laboratories, for its ability to
specifically label cells in eMF biopsies using CD biopsies as
the controls. TOX, although showing no significant staining
in CD, demonstrated intense staining of cells in eMF skin
biopsies, not only in the dermis but also in the epidermis of
eMF samples, including the MF cells in the Pautrier’s
microabscess (Figure 2b).
DISCUSSION
The diagnosis of early-stage MF has been a challenge because
of the large variation in clinical manifestations and lack of
positive histological markers. MF is clinically similar to a
variety of benign inflammatory skin disorders, such as CD,
psoriasis, pigmented purpuric dermatitis, and even vitiligo,
often leading to misdiagnosis and delayed diagnosis that
occasionally exceeds a decade (Arai et al., 1991). The ISCL
criteria have described a series of clinical and histopatholo-
gical features of eMF (Olsen et al., 2007). The proposed
algorithmic scoring approaches for evaluating eMF provide a
degree of diagnostic standardization. However, this approach
involves subjective evaluation standards, which largely rely
upon the experience of the pathologists, and thus may not be
practical in some centers (Furmanczyk et al., 2010). In a
large-scale histology study, Massone et al. (2005) reported
that only 19% MF cases presented Pautrier’s microabscesses,
Table 2. Specifically upregulated genes in eMF compared with CD and NS1
Gene
symbol
P-value
(uncorrected)2
P-value
(corrected)3
Expression ratio
(eMF/NS)
Expression ratio
(eMF/BID)
Expression ratio
(BID/NS) Putative function
TOX 1.65E–06 0.0496 10.38 5.36 1.94 Lymphocyte development
PDCD1 1.63E–06 0.0222 8.43 4.58 1.84 Apoptosis regulation
IL23R 1.30E–06 0.0391 7.65 3.96 1.93 Immune regulation
PYHIN1 5.51E–09 0.0002 7.21 3.74 1.93 Signal transduction
TAGAP 1.13E–06 0.0340 5.25 3.12 1.68 Immune regulation
SKAP1 4.58E–07 0.0137 6.10 3.08 1.98 Signal transduction
HLA-DPB2 1.13E–06 0.0338 4.60 2.94 1.56 Immune regulation
GBP2 1.57E–06 0.0470 4.54 2.86 1.59 Signal transduction
LY9 1.59E–06 0.0478 5.31 2.71 1.96 Immune regulation
ETS1 1.21E–06 0.0363 4.41 2.59 1.70 Signal transduction
AGAP2 5.32E–08 0.0016 4.17 2.49 1.68 Signal transduction
MGAT4A 1.62E–06 0.0485 3.52 2.46 1.43 Cell adhesion
GNGT2 1.06E–06 0.0318 4.54 2.36 1.92 Signal transduction
IL18BP 3.75E–08 0.0011 4.56 2.32 1.97 Immune regulation
TNFSF13B 1.07E–07 0.0032 3.75 2.23 1.68 Immune regulation
PSME2 3.53E–07 0.0106 3.12 2.11 1.48 Signal transduction
IFITM1 2.28E–08 0.0007 3.26 2.08 1.57 Immune regulation
TNFSF10 4.12E–08 0.0012 3.71 2.06 1.80 Immune regulation
LAT 1.00E–06 0.0301 3.67 2.05 1.79 Immune regulation
1Skin biopsies were prepared from early mycosis fungoides (eMF), benign chronic dermatitis (CD), and normal skin (NS), and placed in RNAlater
preservative solution before messenger RNA extraction, and subjected to transcriptome analysis using Agilent whole genome microarrays containing 41,059
unique transcripts. Listed here are genes specifically upregulated in eMF group compared with both CD and NS. The putative function of each gene is shown
in the last column.
2The uncorrected P-values represent Volcano plot filtering using GeneSpring software (7.3) using unpaired two tailed t-test.
3After Bonferroni correction for multiple testing, the corrected P-values were obtained.
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and atypical lymphocytes were present in only 9% of the
cases. Even epidermitropism, a pathognomonic phenomenon
in MF, is completely missing in 4% MF cases (Massone et al.,
2005). Therefore, a positive histological marker for MF cells
would be of considerable value in the diagnosis of MF,
especially in early stages, when the malignant cells are few
in number.
In this eMF-centered transcriptome analysis, a two-stepped
approach was taken to identify genes more specifically
enriched in eMF. First, 349 genes were found to be
differentially expressed in eMF compared with NS. Most of
these genes regulate inflammation and immune activation,
including almost all genes previously reported in MF (Shin
et al., 2007; Litvinov et al., 2010). Together, these genes
regulate inflammation and T-cell activation pathways, as well
as apoptosis, consistent with earlier demonstration that
cutaneous T-cell lymphomas contained apoptosis abnormal-
ities (Fargnoli et al., 1997; De Panfilis, 2002; Klemke et al.,
2009; Wang et al., 2011). However, most of these genes did
not appear to be promising diagnostic markers for eMF, as the
TOX CD4 Merge Merge+DAPI
eMF
CD
eMF
CD
Figure 2. Staining of TOX protein in early mycosis fungoides (eMF) and chronic dermatitis (CD). (a) Frozen sections (4 mm) of eMF and CD biopsies were
stained with a specific rabbit polyclonal antibody against TOX protein (red) and a mouse monoclonal antibody against CD4 antigen (green; see Materials and
Methods section) using multicolored immunofluorescence protocol. The 4,6-diamidino-2-phenylindole (DAPI) stain was used to visualize the nuclei of cells.
(b) Punch biopsies of lesional skin were obtained from patients with eMF and CD and immediately frozen in embedding medium at 80 1C (Tissue-Tek;
Sakura Finetek, Torrance, CA). The biopsies were then cut with a cryostat into 4-mm-thick sections for immunohistochemistry analysis. Briefly, the sections
were fixed in 4% paraformaldehyde at 4 1C for 20minutes and subjected to standard immunohistochemistry protocol using the Vector Elite ABC kit (Vector
Laboratories, Burlingame, CA). The sections were incubated in polyclonal anti-TOX antibody (Sigma-Aldrich, Oakville, ON, Canada). The stained samples were
viewed under a Motic light microscope (Motic, Richmond, BC, Canada). (Top panels) Patch-stage MF. Shown are epidermotropic MF cells in a Pautrier’s
microabscess and papillary dermal MF cells staining positive with TOX antibody (original magnification 400). (Bottom panels) Chronic dermatitis; no
significant TOX staining in the epidermis or in the dermis. Bar¼ 50 mm.
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vast majority of them (N¼330) were also enriched in CD,
which mimics eMF both in clinical appearance and in
histological presence of inflammatory cell infiltrates. There-
fore, a second step was used to filter out these genes, leaving
19 genes with specific enrichment in eMF but not in CD
when compared with NS. Among these, TOX had emerged as
a sensitive and specific marker for eMF biopsies.
Although the exact identity of the TOX-positive cells in
eMF warrants further elucidation, several lines of observation
in this study strongly suggest that they are the MF cells. First,
all Pautrier’s microabscesses in the IHC- and IF-evaluated
samples contain TOXþ CD4þ T cells (Figure 2); second,
TOXþ cells only represent a subset of CD4þ T cells in the
skin biopsies that only came from patients with confirmed
eMF diagnosis, with bright diffused nuclear staining not
observed in any CD4þ cells from CD biopsies; and third,
in the eMF tissues, the cells with TOX staining were the
atypical-appearing cells, with large and atypical nuclei.
TOX antibody did not label the CD4þ cells with small
round nuclei in the eMF biopsies. Finally, TOX antibody did
not label CD8þ T cells, or cells identified with CD1a. It is
worth noting that the eMF samples demonstrating no T-cell
receptor gene rearrangements also contained TOXþ CD4þ
T cells. It remains to be seen whether in these biopsies TCR
clonality could be demonstrated in purified TOXþ cells, an
issue needing further clarification in the future. It appeared
that the cell-based analyses (IF and IHC) demonstrated
stronger specificity and sensitivity of TOX than the whole-
biopsy-based analysis such as reverse transcription–coupled
PCR in this study.
Several previous reports demonstrated numerous genes with
enriched expression in MF, including CXCR3 (Lu et al., 2001),
IL15 (Asadullah et al., 2000; Leroy et al., 2001), IL23 (Doherty
et al., 2006), and b-defensin (Gambichler et al., 2007).
In addition, Tracey et al. (2003) reported 27 genes that separated
MF from inflammatory dermatoses, and constructed a six-gene
prediction model capable of distinguishing MF and inflammatory
disease, including FJX1, Hs. 127160, STAT4, SYNE-1B,
TRAF1, and BIRC3. More recently, researchers identified
593 genes with 41.5-fold differential changes in MF, and
these genes were able to divide MF subjects into three distinct
clusters that had differential progression outcomes (Shin
et al., 2007; Litvinov et al., 2010). However, none of these
studies primarily focused on eMF. Furthermore, although
most of the genes identified by these studies were also found
to be enriched in eMF samples in this study, they did not
appear to be specific to eMF tissues, as they were also found
to be upregulated in CD (Supplementary Table S1 online). In
addition, none of the previously identified MF markers have
been used on skin histological examination of MF skin
biopsies. All 19 genes found to be specifically enriched in
eMF in this study are observations that, to our knowledge, are
previously unreported. The most significantly upregulated
genes by microarray analysis were TOX and PDCD1,
whereas TOX expression was confirmed at both messenger
RNA and cellular levels using multiple strategies, including
routine IHC. PDCD1 expression, which demonstrates lower
significance at the mRNA level (Po0.01 vs. Po0.0001 for
TOX), is highly variable at the protein level. Thus, its
potential as a diagnostic marker for eMF is limited.
TOX encodes a nuclear protein of the high-mobility group
family and is highly but transiently expressed in thymic tissue
(Wilkinson et al., 2002). The high-mobility group box
proteins contain DNA-binding domains that allow them to
modify chromatin structure by bending and unwinding DNA
backbone (Bustin, 1999; Thomas and Travers, 2001), and
therefore they function as transcription factors. TOX expres-
sion has been shown to be strictly regulated in thymocyte
differentiation. Upon maturation of CD4þ T cells, however,
it is switched off before the CD4þ cells exit the thymus, and
is never again expressed to a significant level in mature
CD4þ T cells, which is consistent with our finding that all
CD4þ cells in BID do not demonstrate TOX staining.
Experimentally induced expression of TOX results in a
perturbation in lineage commitment due to reduced sensitiv-
ity to TCR-mediated signaling (Wilkinson et al., 2002).
Here we showed that eMF-infiltrating T cells, including
the epidermotropic T cells, express the TOX protein. The
timing of aberrant expression of TOX in the development of
MF cells is not yet clear. MF cells may re-express TOX extra-
thymically or they may never have stopped TOX expression
during their development. Further investigations are needed
to clarify this issue, and to examine whether TOX expression
is pathogenically relevant for the development of MF.
Table 3. Immunofluorescence detection of TOX and
PDCD1 in eMF and CD1
Percent of CD4+ T cells staining
positive by immunofluorescence
TOX nuclear staining
Subject
no.
Number of CD4+
cells scored2 Bright diffused3 Dim focal4
PDCD1
staining5
MF-4 133 41% 9% 0
MF-5 60 60% 10% 7%
MF-6 140 11% 9% 5%
MF-7 175 69% 9% 24%
MF-8 160 64% 11% 35%
MF-9 99 41% 13% NA
MF-11 190 18% 13% 9%
MF-12 130 19% 15% 3%
CD 1 84 0 0 6%
CD 2 113 0 3% 0
CD 3 126 0 5% 85%
CD 4 71 0 3% 2%
Abbreviations: CD, chronic dermatitis; eMF, early mycosis fungoides;
NA, not available.
1Immunofluorescence staining of 4mm sections were performed accord-
ing to multicolored protocol detailed in the text.
2Average number of CD4+ cells per high-power view (average of 3).
3Bright, diffused nuclear staining.
4Dim, and focal/dot-like nuclear staining.
5Cytoplasmic membrane staining.
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MATERIALS AND METHODS
Skin biopsies of eMF, BID, and NS
Lesional skin biopsies were obtained using 3mm punches under
local anesthesia from 21 patients with eMF (patch and early plaque;
Olsen et al., 2007) recruited from the Skin Lymphoma Clinic of
British Columbia Cancer Agency and the outpatient dermatology
clinics of the Vancouver General Hospital (N¼ 12) and the Depart-
ment of Dermatology and Venerology, Peking University First Hospital,
Beijing, China (N¼ 9), with approval from the Clinical Ethics Board
of both institutions, in accordance with the Declaration of Helsinki
Principles (Molecular Disease Markers, Approval Number C98-0493).
Patients were diagnosed and staged based on clinical history,
physical examination, histology findings, and immunophenotypic
characteristics according to previously described criteria (Olsen et al.,
2007). We enrolled patients with stage IA-IB disease. Patients were
28–82 years of age, with the average age being 49.5 years. Patient
demographics are listed in Table 1. As controls, skin biopsies were
obtained from healthy volunteers (N¼ 21) and 15 subjects with BID,
including psoriasis (n¼ 6), CD (n¼ 6), and pityriasis rubra pilaris
(n¼ 3). The biopsies were placed into RNAlater solutions (Invitrogen,
Burlington, ON, Canada) and stored at 20 1C until RNA extraction.
RNA isolation and gene transcription profiling
Total cellular RNA was extracted using the RNeasy Mini Kit
(Qiagen, Mississauga, ON, Canada) according to the manufacturer’s
instructions. To prepare fluorescently labeled probes for DNA
TOX
TOX
TOX
Merge
eMF
eMF
eMF
CD
CD
CD
CD8
CD1a Merge
Merge
Merge +DAPI
Merge +DAPI
Merge +DAPIPDCD1
Figure 3. Staining of TOX, CD8, CD1a, and PDCD1 in early mycosis fungoides (eMF) and chronic dermatitis (CD). Frozen sections (4 mm) of eMF and
CD biopsies were stained with a specific rabbit polyclonal antibody against TOX protein (red) and a mouse monoclonal antibody against CD8 (a, green),
CD1a (b, green), or PDCD1 (c, green). To visualize the nucleus of cells, 4,6-diamidino-2-phenylindole (DAPI) counterstaining was also performed (blue).
Original magnification  400. Bar¼ 50 mm.
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microarray experiments, 500 ng RNA was reverse transcribed and
linearly amplified by in vitro transcription in the presence of
fluorescent-labeled cytosine triphosphate using the Low RNA Input
Linear Amplification Kit, following the manufacturer’s instructions
(Agilent Technologies, Mississauga, Canada). Two-color transcrip-
tome experiments were conducted, with each experimental sample
(5 eMF, 5 CD, and 15 NS) labeled with Cy5. As a reference, a
common Cy3-labeled reference sample was prepared from a
mixture of healthy skin samples by mixing equal proportions of
the 15 skin biopsies, and used for every experimental sample
(N¼ 25). The Whole Human Genome Oligo microarrays
(G4112F; Agilent Technologies) comprising 41,059 60-nt oligo-
nucleotide probes were used for the hybridization. The Agilent
DNA Microarray Scanner was used for image acquisition and
initial intensity analyses for Cy5 and Cy3 signals from each probe,
separately. After quartile normalization, the samples were
analyzed using the GeneSpring software, version 7.3 (Agilent
Technologies, Mississauga, Canada). Every microarray passed the
standard for quality control purposes and was used for subsequent
analysis (Supplementary Figure S1 online).
Clustering and pathway analysis
Two different algorithms were adopted to evaluate contribution of
gene pathways to the transcriptional differentiation of samples. (1)
Gene Ontology (GO) analysis: GO is a collaborative and compre-
hensive gene annotation resource compiled by the Gene Ontology
Consortium (Ashburner et al., 2000). GO annotations were obtained
from Agilent microarray platform, and the enrichment of biological
annotation terms in selected gene lists were statistically analyzed
with DAVID Bioinformatics Resources 6.7 (Huang da et al.,
2009a, b). The enriched annotation terms associated with the
selected gene list provide insights about the biological themes
behind the transcriptional profiles. After the enriched GO term
lists have been generated, a modular enrichment analysis tool was
used to classify these lists and to avoid the highly redundant
annotations. All annotation sets were ranked by enrichment score
and Benjamini adjusted P-value. (2) Molecular pathway analysis:
Selected gene lists were mapped to Biocarta (Biocarta, San Diego,
CA), with 274 molecular pathways involved in adhesion,
apoptosis, cell activation, cell-cycle regulation, cell signaling,
cytokines and chemokines, developmental biology, hematopoi-
esis, immunology, metabolism, and neurosciences. The enrich-
ment of pathways was also analyzed using DAVID Bioinformatics
Resources 6.7.
Identification of differentially expressed genes in eMF
Given the large number of differentially expressed genes the 41K
transcripts expression profile study would generate, we performed
a robust data analysis with the following strategy. First, only the
genes with expression intensities 4100 in at least 5 of the 25
samples tested are analyzed further to avoid false positives from
low-abundance genes. Second, we applied stringent filtering
methods using Bonferroni correction of P-values set at 0.05,
and fold changes set at 42. Finally, additional filtering was
performed by removing all genes that showed significant
(X2-fold) over-expression in BID (such as CD), leaving only 19
genes showing selective enrichment in eMF but not in CD when
compared with NS.
Confirmation with quantitative real-time PCR
RNA was reverse transcribed using random primers and SuperScript
III reverse transcriptase (Invitrogen). Real-time PCR was performed
and analyzed with glyceraldehyde-3-phosphate dehydrogenase and
18S genes as the internal controls.
The results are expressed as copies of the specific genes per 1,000
copies of glyceraldehyde-3-phosphate dehydrogenase. The formula
for the calculation of transcript abundance was as previously
reported (Su et al., 2003; Wang et al., 2011).
IF and IHC studies
Cryosections of lesional skin from eMF patients and controls were
fixed with 4% ice-cold paraformaldehyde. After permeabilization
and blocking, slides were incubated with rabbit anti-TOX polyclonal
antibody (Sigma-Aldrich, St Louis, MO) and mouse monoclonal anti-
human CD4 antibody (Dako, Mississauga, ON, Canada). This was
followed by double staining with Alexa-594-conjugated secondary
antibody (Red) and Alexa-488-conjugated secondary antibody
(green; Life Technologies, Burlington, ON, Canada). Cell nuclei
were counterstained with 4,6-diamidino-2-phenylindole before
being mounted with Fluorescence Mounting Medium (Dako).
Images were collected and processed by fluorescence microscope.
IHC was performed using methods previously reported (Dai et al.,
2003; Zhou et al., 2005; Tang et al., 2006; Tang and Su et al., 2008;
Wang et al., 2010).
Statistical analysis
The GeneSpring Software (version 7.3) was used for transcriptome
analysis, including the filtering based after Bonferroni correction for
multiple testing, clustering analysis, pathway analysis, as well as
heat-map construction.
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